Advertisement

International Journal of Clinical Pharmacy

, Volume 40, Issue 4, pp 842–851 | Cite as

Reporting adverse drug reactions: contribution, knowledge and perception of German pharmacy professionals

  • Anna LavenEmail author
  • Katharina Schmitz
  • Wilhelm-Hubertus Franzen
Research Article

Abstract

Background The detection, assessment and prevention of adverse drug reactions along the product’s life cycle is known as pharmacovigilance. German pharmacists are obliged by law to conduct pharmacovigilance measures, a specific training is not required. Objectives To assess the knowledge, contribution and perception of German pharmacy professionals regarding pharmacovigilance activities, in order to identify their needs to report better on the issue. Setting A semi-quantitative survey among German pharmacy professionals was conducted in November 2017. Method A questionnaire with 20 questions was developed and distributed to pharmacy professionals in four different German regions. Main outcome measures To assess the knowledge the number of right answered questions were examined; for perception a six-point-Likert was used and for contribution, yes or no questions. Results The participation ratio was 64.5% (n = 127). Nearly half of the participants (47.2%, n = 60) stated that they had already reported adverse drug reactions. Regarding the knowledge questions, there was neither a statistically significant difference between the correct answers of pharmacists and pharmacy technical assistents (p = 0.7209), nor between the different regions (p > 0.5054). For better reporting, the participants recommended better training, shorter forms to fill in and/or a contact person to call. Conclusion For the successful integration of pharmacovigilance reporting in daily practice, we suggest the following: (1) A structured, mandatory training of the pharmacy team. (2) The preparation of a standard operating procedure for the pharmacy or its integration into the pharmacy software.

Keywords

Adverse drug reactions Community pharmacy Germany Pharmacovigilance Questionnaire Survey 

Notes

Acknowledgements

The authors thank Julia Franzen for the statistical analysis in R, John Bradshaw for language editing and the participating pharmacists and PTAs for their time and dedication to furthering the understanding of pharmacovigilance patterns in German pharmacies.

Funding

This study was not supported financially.

Conflicts of interest

Both LA and SK work for Pharmabrain, a company specialising in continuing education for pharmacy teams. FWH declares that he has no conflict of interest.

References

  1. 1.
    The European Commission. Commission Implementing Regulation (EU) No. 520/2012 (June 19th 2012).Google Scholar
  2. 2.
    Arzneimittelgesetz in der Fassung der Bekanntmachung vom 12. Dezember 2005 (BGBl. I S. 3394), das zuletzt durch Artikel 1 des Gesetzes vom 18. Juli 2017 (BGBl. I S. 2757) geändert worden ist. German.Google Scholar
  3. 3.
    Bundesinstitut für Arzneimittel und Medizinprodukte (Internet). Bonn: BfArM. Eingänge zu UAW-Berichten. https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/Gremien/RoutinesitzungPar63AMG/80Sitzung/pkt-2-1-1.pdf?__blob=publicationFile&v=2. Accessed 23 Apr 2018. German.
  4. 4.
    Apothekenbetriebsordnung in der Fassung der Bekanntmachung vom 26. September 1995 (BGBl. I S. 1195), die durch Artikel 11 Absatz 7 des Gesetzes vom 18. Juli 2017 (BGBl. I S. 2745) geändert worden ist. German.Google Scholar
  5. 5.
    Bundesvereinigung Deutscher Apothekerverbände e.V (Internet). Berlin: ABDA. Referenzapotheken. https://www.abda.de/themen/arzneimittelsicherheit/amk/wir-ueber-uns/referenzapotheken/. Accessed 23 Apr 2018. German.
  6. 6.
    Borg JJ, Aislaintner G, Pirozynski M, Mifsud S. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Drug Saf. 2011;34:187–97.CrossRefPubMedGoogle Scholar
  7. 7.
    Keller E. Unerwünschte Arzneimittelwirkungen: Ansätze zur Inzidenzschätzung und Signalgenerierung mit fallbasierten Pharmakovigilanzdaten (dissertation). Ludwig-Maximilians-Universität zu München. 2006. German.Google Scholar
  8. 8.
    Bundesvereinigung Deutscher Apothekerverbände e.V (Internet). Berlin: ABDA. UAW Berichtsbogen. https://www.abda.de/themen/arzneimittelsicherheit/amk/amk-berichtsboegen/uaw-berichtsbogen/. Accessed 23 Apr 2018. German.
  9. 9.
    Arzneimittelkommission der deutschen Ärzteschaft (Internet). Berlin: AkdÄ. Bericht über unerwünschte Arzneimittelwirkungen. https://www.dcgma.org/uaw-meldung/. Accessed 23 Apr 2018. German.
  10. 10.
    Bundesinstitut für Arzneimittel und Medizinprodukte (Internet). Bonn: BfArM. Meldung von Verdachtsfällen unerwünschter Arzneimittelwirkungen und Impfkomplikationen. https://humanweb.pei.de/index_form.php. Accessed 23 Apr 2018. Accessible after Login. German.
  11. 11.
    Paul-Ehrlich Institut (Internet). Langen: PEI. Meldung von Verdachtsfällen unerwünschter Arzneimittelwirkungen und Impfkomplikationen. https://humanweb.pei.de/index_form.php. Accessed 23 Apr 2018. Accessible after Login. German.
  12. 12.
    European Medicines Agency (Internet). London: EMA. EudraVigilance: electronic reporting. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000686.jsp&mid=WC0b01ac0580a69261. Accessed 23 Apr 2018.
  13. 13.
    R Development Core Team. R: A language and environment for statistical computing. Version 3.3.2 (software). Vienna: The R Foundation for Statistical Computing. http://www.R-project.org/. Accessed 23 Apr 2018.
  14. 14.
    Embryotox (Internet). Berlin: Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum Augustenburger Platz 1, 13353 Berlin. http://www.embryotox.de. Accessed 23 Apr 2018. German.
  15. 15.
    Hazell L, Shakir S. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385–96.CrossRefPubMedGoogle Scholar
  16. 16.
    Alsaleh FM, Alzaid SW, Abahussain EA, Bayoud T, Lemay J. Knowledge, attitude and practices of pharmacovigilance and adverse drug reaction reporting among pharmacists working in secondary and tertiary governmental hospitals in Kuwait. Saudi Pharm J. 2017;25:830–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Su C, Ji H, Su Y. Hospital pharmacists’ knowledge and opinions regarding adverse drug reaction reporting in Northern China. Pharmacoepidemiol Drug Saf. 2010;19:217–22.CrossRefPubMedGoogle Scholar
  18. 18.
    Dorji C, Tragulpiankit P, Riewpaiboon A, Tobgay T. Knowledge of adverse drug reaction reporting among healthcare professionals in Bhutan: a cross-sectional survey. Drug Saf. 2016;39:1239–50.CrossRefPubMedGoogle Scholar
  19. 19.
    Santosh KC, Tragulpiankit P, Gorsanan S, Edwards IR. Attitudes among healthcare professionals to the reporting of adverse drug reactions in Nepal. BMC Pharmacol Toxicol. 2013;14:16.CrossRefPubMedGoogle Scholar
  20. 20.
    Ali MD, Hassan YA, Ahmad A, Almahmoud S, Alagel O, Al-Harbi HK, et al. Knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting process among health care providers in Dammam, Saudi Arabia. Curr Drug Saf. 2017;2018(13):21–5.Google Scholar
  21. 21.
    Pimpalkhute SA, Jaiswal KM, Sontakke SD, Bajait CS, Gaikwad A. Evaluation of awareness about pharmacovigilance and adverse drug reaction monitoring in resident doctors of a tertiary care teaching hospital. Indian J Med Sci. 2012;66:55–61.CrossRefPubMedGoogle Scholar
  22. 22.
    Santosh KC, Tragulpiankit P, Edwards IR, Gorsanan S. Knowledge about adverse drug reactions reporting among health care professionals in Nepal. Int J Risk Saf Med. 2013;25:1–16.PubMedGoogle Scholar
  23. 23.
    Chhabra KG, Sharma A, Chhabra C, Reddy JJ, Deolia SG, Mittal Y. Knowledge, attitude, and practices regarding pharmacovigilance and adverse drug reaction reporting among dental students in a Teaching Hospital, Jodhpur, India: a cross-sectional study. J Contemp Dent Pract. 2017;18:964–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Terblanche A, Meyer JC, Godman B, Summers RS. Knowledge, attitudes and perspective on adverse drug reaction reporting in a public-sector hospital in South Africa: baseline analysis. South Afr Hosp Pract. 1995;2017(45):238–45.Google Scholar
  25. 25.
    DESTATIS (Internet). Wiesbaden: Statistisches Bundesamt Gesundheit: Personal. https://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Gesundheitspersonal/Personal.html, Article No. 2120731157004. Accessed 23 Apr 2018. German.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pharmabrain GmbH, Research and Training CenterBerlinGermany
  2. 2.Takeda Pharma Vertrieb GmbH & Co. KGBerlinGermany

Personalised recommendations